Alzheimer's & Dementia

Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial

By Martí Jiménez-Mausbach, Betty Marije Tijms, Clare Paterson, Jan Christian Refsgaard

Randomised trial in 2,970 peopleInterventions

104 weeks, placebo-controlled

The paper

Martí Jiménez-Mausbach, Betty Marije Tijms, Clare Paterson, Jan Christian Refsgaard

Novo Nordisk (Denmark)

Alzheimer's & Dementia, 8 Aug 2026

doi.org/10.1002/dad2.70432 PubMed 42571323

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
International Journal of Obesity8 Oct 2026
Weight-loss surgery linked to lower dementia and Parkinson's risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19